Physician profile
Joshua K Johnston
NPI 1013929520
$992,979.64
in general payments reported to CMS, 2019-2025
36 companies · $252K in 2025
The $252K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55K · 2020: $103K · 2021: $139K · 2022: $165K · 2023: $122K · 2024: $157K · 2025: $252K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $227K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $137K · Consulting Fee: $64K · Travel and Lodging: $58K · Honoraria: $26K · Food and Beverage: $19K · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $226,774.32 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $136,925.00 |
| Consulting Fee | $64,014.53 |
| Travel and Lodging | $58,256.40 |
| Honoraria | $26,200.00 |
| Food and Beverage | $18,756.64 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $314,192.87 | 2019-2025 | Cequa |
| Allergan, INC. | $176,385.06 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $126,080.30 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $107,993.54 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $46,552.82 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sight Sciences, INC. | $45,665.81 | 2019-2025 | Tearcare System |
| Harrow Eye, LLC | $41,898.11 | 2024-2025 | Vevye, Triesence |
| Abbvie INC. | $35,757.75 | 2022-2025 | |
| Alcon Vision LLC | $23,439.79 | 2019-2025 | Tryptyr, Rocklatan, Eysuvis |
| Dompe US, INC. | $17,269.27 | 2020-2025 | Oxervate |
| Biotissue Holdings INC. | $14,827.67 | 2019-2025 | |
| Nordic Pharma, INC. | $8,400.00 | 2024-2025 | Lacrifill, Lacrifill |
| Kala Pharmaceuticals, INC. | $8,329.10 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $8,305.76 | 2019-2022 | |
| Alcon Research LLC | $4,161.89 | 2019-2025 | Tryptyr |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,506.49 | 2019-2022 | |
| Horizon Therapeutics Plc | $2,344.25 | 2020-2023 | Tepezza |
| Glaukos Corporation | $2,023.54 | 2019-2025 | Photrexa Viscous and Photrexa |
| Tearlab Corp | $1,672.11 | 2022-2023 | Tearlab Osmolarity System |
| Carl Zeiss Meditec, INC. | $1,534.87 | 2019-2021 | |
| Seagen INC. | $990.00 | 2022 | |
| Quidel Corporation | $633.74 | 2019-2021 | |
| Shire North American Group INC | $390.28 | 2019 | |
| Topcon Healthcare, INC. | $259.43 | 2024-2025 | |
| Thea Pharma INC. | $250.00 | 2022 | |
| Ani Pharmaceuticals, INC. | $245.15 | 2024-2025 | Purified Cortrophin Gel |
| Rxsight INC | $174.58 | 2022-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Carl Zeiss Meditec USA, INC. | $158.84 | 2025 | Cirrus Hd-Oct |
| Mallinckrodt Hospital Products INC. | $143.68 | 2021-2023 | Acthar |
| Eyevance Pharmaceuticals LLC | $114.77 | 2019-2021 | |
| Stryker Corporation | $87.66 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $48.07 | 2019-2021 | |
| Alimera Sciences, INC. | $45.29 | 2024 | Yutiq, Iluvien |
| Aerie Pharmaceuticals, INC. | $39.23 | 2019-2020 | |
| Ocular Therapeutix, INC. | $32.92 | 2019 | |
| Amgen INC. | $25.00 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.